Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.

NCT07460986 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT07460986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07460986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.
Lead sponsor
MedSIR
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 20, 2026
Completion date
October 31, 2028
Enrollment
278 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

soft tissue sarcoma (sts)